FDA label
What is Anoro Ellipta used for?
Anoro Ellipta contains umeclidinium bromide and vilanterol trifenatate. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “ANORO ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Anoro Ellipta?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Anoro Ellipta, powder
Indications and Usage, quoted from the label by GlaxoSmithKline LLC (NDA203975). Cross-references to other label sections are left out.
ANORO ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Limitations of Use
ANORO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma. The safety and effectiveness of ANORO ELLIPTA in asthma have not been established.
Source: DailyMed label, set id 2dbd0671-c565-40c5-bf0f-e324db26799c, version 29, effective June 2, 2023. NDC 0173-0869, one of 1 listing for this product.
Questions
What is Anoro Ellipta used for?
The FDA label says: “ANORO ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).”
What drug class is Anoro Ellipta?
FDA lists umeclidinium bromide and vilanterol trifenatate in the Anticholinergic and beta2-Adrenergic Agonist established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.